MY191697A - Use of the pacap as a molecular adjuvant for vaccines - Google Patents
Use of the pacap as a molecular adjuvant for vaccinesInfo
- Publication number
- MY191697A MY191697A MYPI2014700419A MYPI2014700419A MY191697A MY 191697 A MY191697 A MY 191697A MY PI2014700419 A MYPI2014700419 A MY PI2014700419A MY PI2014700419 A MYPI2014700419 A MY PI2014700419A MY 191697 A MY191697 A MY 191697A
- Authority
- MY
- Malaysia
- Prior art keywords
- pacap
- vaccines
- adjuvant
- aquatic organisms
- molecular adjuvant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 101150060255 MZB1 gene Proteins 0.000 title 1
- 101100462550 Mus musculus Adcyap1 gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 108060000200 adenylate cyclase Proteins 0.000 abstract 1
- 102000030621 adenylate cyclase Human genes 0.000 abstract 1
- 244000078703 ectoparasite Species 0.000 abstract 1
- 230000005745 host immune response Effects 0.000 abstract 1
- 238000007654 immersion Methods 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011000167A CU24075B1 (es) | 2011-08-26 | 2011-08-26 | Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular. |
| PCT/CU2012/000004 WO2013029570A1 (es) | 2011-08-26 | 2012-08-24 | Uso del pacap como adyuvante molecular para vacunas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY191697A true MY191697A (en) | 2022-07-07 |
Family
ID=47046313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014700419A MY191697A (en) | 2011-08-26 | 2012-08-24 | Use of the pacap as a molecular adjuvant for vaccines |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9549977B2 (enExample) |
| EP (1) | EP2749291B1 (enExample) |
| JP (1) | JP6077541B2 (enExample) |
| KR (1) | KR101857705B1 (enExample) |
| CN (1) | CN103874510A (enExample) |
| AU (1) | AU2012303887B2 (enExample) |
| BR (1) | BR112014004620B1 (enExample) |
| CA (1) | CA2844898C (enExample) |
| CL (1) | CL2014000386A1 (enExample) |
| CU (1) | CU24075B1 (enExample) |
| ES (1) | ES2648337T3 (enExample) |
| MX (1) | MX351725B (enExample) |
| MY (1) | MY191697A (enExample) |
| NO (1) | NO2749291T3 (enExample) |
| PH (1) | PH12014500397B1 (enExample) |
| PT (1) | PT2749291T (enExample) |
| RU (1) | RU2580294C2 (enExample) |
| SG (1) | SG11201400215SA (enExample) |
| WO (1) | WO2013029570A1 (enExample) |
| ZA (1) | ZA201401271B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190060057A (ko) | 2017-11-24 | 2019-06-03 | 유병희 | 웰빙 무드등 |
| EP3970796B1 (en) * | 2019-05-14 | 2025-08-20 | Senju Pharmaceutical Co., Ltd. | Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide |
| CN117617183B (zh) * | 2023-11-29 | 2025-09-05 | 中国医学科学院医药生物技术研究所 | 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE65568B1 (en) * | 1990-10-22 | 1995-11-01 | Unilever Plc | Vaccine compositions for fish |
| PE20010612A1 (es) * | 1999-09-28 | 2001-07-12 | Bayer Corp | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico |
| GB0427267D0 (en) * | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
| CU23557A1 (es) | 2005-11-22 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Neuropéptidos para el cultivo de organismos acuáticos |
| CN102883739B (zh) * | 2009-11-02 | 2015-11-25 | 图兰恩教育基金管理人 | 垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法 |
| CN103255089B (zh) * | 2013-05-03 | 2015-08-05 | 中国水产科学研究院黄海水产研究所 | 一株强毒迟缓爱德华氏菌疫苗株及其应用 |
-
2011
- 2011-08-26 CU CU2011000167A patent/CU24075B1/es active IP Right Grant
-
2012
- 2012-08-24 JP JP2014526385A patent/JP6077541B2/ja active Active
- 2012-08-24 PH PH1/2014/500397A patent/PH12014500397B1/en unknown
- 2012-08-24 NO NO12775123A patent/NO2749291T3/no unknown
- 2012-08-24 US US14/238,377 patent/US9549977B2/en active Active
- 2012-08-24 CA CA2844898A patent/CA2844898C/en active Active
- 2012-08-24 CN CN201280041829.5A patent/CN103874510A/zh active Pending
- 2012-08-24 BR BR112014004620-4A patent/BR112014004620B1/pt active IP Right Grant
- 2012-08-24 ES ES12775123.8T patent/ES2648337T3/es active Active
- 2012-08-24 AU AU2012303887A patent/AU2012303887B2/en not_active Ceased
- 2012-08-24 MX MX2014002214A patent/MX351725B/es active IP Right Grant
- 2012-08-24 EP EP12775123.8A patent/EP2749291B1/en active Active
- 2012-08-24 SG SG11201400215SA patent/SG11201400215SA/en unknown
- 2012-08-24 KR KR1020147006186A patent/KR101857705B1/ko active Active
- 2012-08-24 WO PCT/CU2012/000004 patent/WO2013029570A1/es not_active Ceased
- 2012-08-24 MY MYPI2014700419A patent/MY191697A/en unknown
- 2012-08-24 RU RU2014111465/15A patent/RU2580294C2/ru active
- 2012-08-24 PT PT127751238T patent/PT2749291T/pt unknown
-
2014
- 2014-02-14 CL CL2014000386A patent/CL2014000386A1/es unknown
- 2014-02-19 ZA ZA2014/01271A patent/ZA201401271B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012303887B2 (en) | 2017-06-22 |
| PH12014500397B1 (en) | 2018-09-12 |
| KR20140064847A (ko) | 2014-05-28 |
| JP2014524450A (ja) | 2014-09-22 |
| PT2749291T (pt) | 2017-11-24 |
| CA2844898A1 (en) | 2013-03-07 |
| BR112014004620A2 (pt) | 2017-03-21 |
| CU24075B1 (es) | 2015-01-29 |
| EP2749291A1 (en) | 2014-07-02 |
| RU2014111465A (ru) | 2015-10-10 |
| CA2844898C (en) | 2021-06-22 |
| MX351725B (es) | 2017-10-25 |
| CU20110167A7 (es) | 2013-06-28 |
| ZA201401271B (en) | 2015-04-29 |
| US9549977B2 (en) | 2017-01-24 |
| US20140294889A1 (en) | 2014-10-02 |
| JP6077541B2 (ja) | 2017-02-08 |
| MX2014002214A (es) | 2014-04-30 |
| AU2012303887A1 (en) | 2014-03-06 |
| ES2648337T3 (es) | 2018-01-02 |
| RU2580294C2 (ru) | 2016-04-10 |
| BR112014004620B1 (pt) | 2019-10-29 |
| PH12014500397A1 (en) | 2014-04-14 |
| NO2749291T3 (enExample) | 2018-03-17 |
| KR101857705B1 (ko) | 2018-06-20 |
| CL2014000386A1 (es) | 2014-07-11 |
| CN103874510A (zh) | 2014-06-18 |
| EP2749291B1 (en) | 2017-10-18 |
| SG11201400215SA (en) | 2014-09-26 |
| WO2013029570A1 (es) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920240B8 (pt) | composição adjuvante | |
| CL2013003360A1 (es) | “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| ECSP14013315A (es) | Inhibidores de aplicación viral | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| CO6361950A2 (es) | Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1 | |
| PH12015501378B1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
| EA201491969A1 (ru) | Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197 | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| MY191697A (en) | Use of the pacap as a molecular adjuvant for vaccines | |
| MY167069A (en) | Antigen peptide and use thereof | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| CL2014000760A1 (es) | Peptido antimicrobiano aislado y purificado de branquias de tilapia (oreochromis niloticus); acido nucleico que lo codifica; composicion que lo comprende; y su uso para el control de patogenos y como adyuvante molecular en una composicion vacunal para aumentar la respuesta inmune contra el antigeno vacunal. | |
| WO2013084070A3 (en) | Salmonella vaccine proteins | |
| WO2015048785A3 (en) | Mosaic conserved region hiv immunogenic polypeptides | |
| EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
| MX360831B (es) | Virus de influenza c y vacuna. | |
| CL2013001561A1 (es) | Composicion que comprende al polipeptido activador de la adenilato ciclasa de pituitaria (pacap); combinacion veterinaria que comprende al pacap y una molecula antiviral; y uso del pacap para el tratamiento de enfermedades infecciosas causadas por virus en organismos acuaticos. | |
| TH151450A (th) | การใช้ของ pacap ในรูปโมเลกุลสารเสริมฤทธิ์สำหรับวัคซีน | |
| MX2019005122A (es) | Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal. | |
| WO2008084125A3 (es) | Procedimiento para la preparacion de una vacuna frente a la escuticociliatosis en peces marinos en cultivo | |
| TH167525A (th) | อนุพันธ์ของไซโคลสปอรินชนิดใหม่สำหรับการรักษาและป้องกันการติดเชื้อไวรัส | |
| TH159902A (th) | สารประกอบเบนโซฟิวแรนสำหรับรักษาการติดเชื้อไวรัสตับอักเสบ c | |
| CO6290680A2 (es) | Inhibidores de virus de la hepatitis c |